Copyright
©The Author(s) 2018.
World J Gastroenterol. Dec 28, 2018; 24(48): 5418-5432
Published online Dec 28, 2018. doi: 10.3748/wjg.v24.i48.5418
Published online Dec 28, 2018. doi: 10.3748/wjg.v24.i48.5418
Target type | Target molecule | Vaccination strategy | Therapy | Number of patients | Trial identifier |
TAA | CEA | alphavirus replicon (VRP) encoding CEA | 12 | NCT01890213 | |
TAA | CEA | ETBX-011 ad-CEA, ALT-803 (IL-15) | 3 | NCT03127098 | |
TAA | CEA | anti-CEA CAR-T cells | 18 | NCT03682744 | |
TAA | CEA | anti-CEA CAR-T cells | 5 | NCT02850536 | |
TAA | CEA | anti-CEA CAR-T cells, SIR-Sphere | 8 | NCT02416466 | |
TAA | Her2 | 2 Her2 peptides in Montanide ISA 720 | 36 | NCT01376505 | |
TAA | Her2/neu | B-Cell and monocytes with HER2/neu antigen | 9 | NCT03425773 | |
TAA | Brachyury, CEA, MUC1 | ETBX-051; adenoviral brachyury vaccine, ETBX-061; adenoviral MUC1 vaccine, ETBX-011; adenoviral CEA vaccine | 32 | NCT03384316 | |
TAA | 7 cancer testis antigens | 6 synthetic peptides in Montanide | Standard-of care maintenance | 15 | NCT03391232 |
Immune stimulation, TAA | MUC1 | activated CIK and CD3-MUC1 bispecific antibody | cryotherapy | 90 | NCT03524274 |
TAA | HPV | DPX-E7 | 44 | NCT02865135 | |
TAA | hTERT | INO-1400 or INO-1401 alone or in combination with INO-9012 | 93 | NCT02960594 | |
TAA | MUC1 | anti-MUC1 CAR-pNK cells | 10 | NCT02839954 | |
TAA | MUC1 | MUC1 peptide-poly-ICLC | 110 | NCT02134925 | |
TAA | EpCAM | CAR T Cells targeting EpCAM | 60 | NCT03013712 | |
Immune checkpoint, TAA | PD-1, p53 | Pembrolizumab, modified vaccinia virus Ankara vaccine expressing p53 | 19 | NCT02432963 | |
Neoantigen | frameshift-derived neoantigen-loaded DC | 25 | NCT01885702 | ||
Neoantigen | personalized neoepitope yeast-based vaccine, YE-NEO-001 | 16 | NCT03552718 | ||
Neoantigen | mRNA-based vaccine targeting neoantigens | 64 | NCT03480152 | ||
Neoantigen | ADXS-NEO (Advaxis NEO expressing personalized tumor antigens) | 48 | NCT03265080 | ||
Neoantigen | ras | anti-KRAS G12 V mTCR | Cyclophosphamide, Fludarabine, Aldesleukin | 110 | NCT03190941 |
Immune checkpoint | PD-L1 | Avelumab, autologous dendritic cells | 33 | NCT03152565 | |
Immune checkpoint | PD-1 | Pembrolizumab, GVAX (allogeneic colon cancer GM-CSF secreting cells) | Cyclophosphamide | 17 | NCT02981524 |
Immune checkpoint | PD-L1 | Atezolizumab, Imprime PGG (PAMP recognized by innate immune effector cells) | Regorafenib/ Isatuximab/ Bevacizumab | 120 | NCT03555149 |
Immune checkpoint | A2aR, A2bR | AB928 (A2aR and A2bR antagonist) | FOLFOX | 98 | NCT03720678 |
Immune checkpoint, TAA | PD-1, CEA, MUC-1 | Nivolumab, MVA-BN-CV301 (modified vaccinia Ankara-Bavarian Nordic encoding CEA, MUC1, B7-1, ICAM-1 and LFA-3) | FOLFOX | 78 | NCT03547999 |
Immune checkpoint, TAA | PD-L1 | Atezolizumab, RO7198457 (mRNA-based individualized, TAAs vaccine) | 567 | NCT03289962 | |
Immune checkpoint, TAA | PD-L1, CEA | Avelumab + Ad-CEA | FOLFOX, Bevacizumab, Capecitabine | 81 | NCT03050814 |
Immune checkpoint, TAA, Immune stimulation | CEA, Her2/neu, Brachyury, MUC1, RAS, NK cells ICI | Aldoxorubicin, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, avelumab, HCI, ALT-803 | Capecitabine, Cetuximab, Cyclophosphamide, Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT, Trastuzumab | 332 | NCT03563157 |
Immune checkpoint, Mutated proteins | PD-1 | Personalized peptides, Pembrolizumab | 60 | NCT02600949 | |
Immune stimulation | GVAX (allogeneic colon cancer GM-CSF secreting cells) | Cyclophosphamide, SGI-110 (DNA Methyltransferase Inhibitor) | 18 | NCT01966289 | |
Immune stimulation | GVAX (allogeneic colon cancer GM-CSF secreting cells) | 15 | NCT01952730 | ||
Immune stimulation | OncoVAX (non-dividing tumor cells) | Surgery | 550 | NCT02448173 | |
Immune stimulation | Autologous or allogeneic immune stimulatory tumor cells | 50 | NCT00722228 | ||
Immune stimulation | autologous dendritic cells loaded with autologous tumour homogenate + IL-2 | 19 | NCT02919644 | ||
Immune stimulation | autologous dendritic cells loaded with tumor antigens | 58 | NCT01348256 | ||
Immune stimulation | autologous dendritic cells loaded with tumor lysate antigens | 30 | NCT03214939 | ||
Oncolytic virus | GL-ONC1 oncolytic vaccinia virus, which disrupts nonessential genes and expression of the foreign gene expression | 36 | NCT02714374 | ||
Oncolytic virus, Immune checkpoint | PD-L1 | Talimogene Laherparepvec, Atezolizumab | 36 | NCT03256344 |
- Citation: Wagner S, Mullins CS, Linnebacher M. Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens. World J Gastroenterol 2018; 24(48): 5418-5432
- URL: https://www.wjgnet.com/1007-9327/full/v24/i48/5418.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i48.5418